Logo
x

Search

Subscribe Now
Logo

PharmaShots Weekly Snapshot (December 03 - 07, 2018)

Share this

Senior Editor

  • Dec 10, 2018

PharmaShots Weekly Snapshot (December 03 - 07, 2018)

1.Genentech’s Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations Published: 6 Dec, 2018 | Tags: Genentech, Tecentriq, Receives, FDA, Approval, Combination Therapy, Treat, mNon-Sq, NSCLC, No EGFR, ALK, Genomic Tumor Aberrations
  1. Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for CRISPR/Cas9-Based Therapy
Published: 6 Dec, 2018 | Tags: Novartis, Reports, Results, BYL719, (alpelisib), fulvestrant, P-III, SOLAR-1, HR+/HER2- Advanced Breast Cancer
  1. Biogen Exercises Exclusive Worldwide Option to Develop & Commercialize Ionis’s BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS)
Published: 6 Dec, 2018 | Tags: Biogen, Exercises, Option, Develop, Commercialize, Ionis, BIIB067, (IONIS-SOD1RX), Amyotrophic Lateral Sclerosis (ALS), SOD1 mutations
  1. Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer
Published: 6 Dec, 2018 | Tags: Novartis, Reports, Results, BYL719, (alpelisib), fulvestrant, P-III, SOLAR-1, HR+/HER2- Advanced Breast Cancer
  1. Subtle an AI based Medical Device SubtlePET Receives FDA’s 510(K) Clearance
Published: 6 Dec, 2018 | Tags: Subtle, AI, based, Medical Device, SubtlePET, Receives, FDA, 510(K) Clearance
  1. Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders
Published: 5 Dec, 2018 | Tags: Roche, Collaborates, Icagen, Development, Drug, Candidates, Neurological Disorders
  1. Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)
Published: 6 Dec, 2018 | Tags: Roche, Reports, Results, Kadcyla, (trastuzumab emtansine), Herceptin, (trastuzumab) P-III, KATHERINE Study, HER2-positive Early Breast Cancer (eBC) 8.NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US Published: 5 Dec, 2018 | Tags: NeuroPace, Reports, Positive, Results, Next-Gen RNS System, Refractory, Epilepsy, the US
  1. Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease
Published: 5 Dec, 2018 | Tags: Innovate, Massachusetts General Hospital, Collaborates, Develop, Alcoholic Liver Diseases, Celiac Disease
  1. Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)
Published: 5 Dec, 2018 | Tags: Domain Therapeutics, Signs, Research, License, Agreement, Boehringer Ingelheim (BI) , G-Protein Coupled Receptors (GPCRs)
  1. Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)
Published: 5 Dec, 2018 | Tags: Celltrion, Reports, Results, CT-P10, (rituximab, biosimilar), P-III, Advance Follicular Lymphoma, Rituxan
  1. Gilead’s Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA ‘s (CFDA) Approval for HIV-1 Infection
Published: 5 Dec, 2018 | Tags: Gilead, Descovy, (Emtricitabine, Tenofovir Alafenamide), Receives, NMPA, CFDA, Approval, HIV-1 Infection 13.Crown Laboratories Acquires Rights for GSK’s Five OTC Drugs Published: 30 Nov, 2018 | Tags: Crown Laboratories, Acquires, Rights, GSK’s, Five, OTC Drugs
  1. Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018
Published: 2 Dec, 2018|Tags: Kite, Reports, Results, Yescarta, (axicabtagene ciloleucel), ZUMA-1, Refractory, Large B-Cell, Lymphoma
  1. Cilag Acquires Exclusive Worldwide Rights of Argenx’s Cusatuzumab (ARGX-110) for $1.6B
Published: 4 Dec, 2018|Tags: Cilag Acquired Exclusive Worldwide Rights of Argenx’s Cusatuzumab (ARGX-110) for $1.6B
  1. AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humira’s (adalimumab) Patent Rights with Pfizer
Published: 4 Dec, 2018|Tags: AbbVie, Signs, Worldwide, Non-Exclusive, License, Agreement, Humira, (adalimumab), Patent, Rights, Pfizer
  1. GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)
Published: 3 Dec, 2018|Tags: GSK, Acquire, Tesaro, Zejula, (niraparib), $5.1B,(£4.0 billion), Ovarian, Prostate, Lung
  1. Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma
Published: 3 Dec, 2018|Tags: Pfizer, Reports, Results, PF-05280586, (rituximab biosimilar), REFLECTIONS B328-06 study, CD20-Positive Non-Hodgkin Lymphoma
  1. Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma
Published: 3 Dec, 2018|Tags: Bluebird Bio, Celgene, Reports, Results, bb21217, P-I, (CRB-402), 3L+, r/r, Multiple Myeloma
  1. Shire’s Takhzyro IV (lanadelumab) Receives EU’s Approval for Hereditary Angioedema
Published: 3 Dec, 2018 | Tags: Shire, Takhzyro, IV, (lanadelumab), Receives, EU, Approval, Hereditary Angioedema

Related News/Articles

Caldera Medical Reports the Acquisition of UVision360, Strengthening its Minimally Invasive Hysteroscopy Portfolio

Caldera Medical Reports the Acquisition of UVision360, Strengthening its Minimally Invasive Hysteroscopy Portfolio

  • October 8, 2024
Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology

Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology

  • October 4, 2024
Orion and Aitia Join Forces for AI-Based Drug Discovery and Drug Simulation in Oncology

Orion and Aitia Join Forces for AI-Based Drug Discovery and Drug Simulation in Oncology

  • September 26, 2024
Top 20 Oncology Companies of 2024

Top 20 Oncology Companies of 2024

  • August 29, 2024
Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma

Servier Reports the US FDA’s Approval of Voranigo (Vorasidenib) to Treat Grade 2 IDH-Mutant Glioma

  • August 7, 2024
New Drug Designations - June 2024

New Drug Designations - June 2024

  • July 30, 2024
PharmaShots Weekly Snapshots (July 01 – July 05, 2024)

PharmaShots Weekly Snapshots (July 01 – July 05, 2024)

  • July 5, 2024
Eleva’s CPV-104 Gains EC’s Orphan Drug Designation to Treat C3 Glomerulopathy (C3G)

Eleva’s CPV-104 Gains EC’s Orphan Drug Designation to Treat C3 Glomerulopathy (C3G)

  • July 5, 2024
PharmaShots Weekly Snapshots (June 10 – June 14, 2024)

PharmaShots Weekly Snapshots (June 10 – June 14, 2024)

  • June 14, 2024
60 Degrees Pharmaceuticals’ Tafenoquine Gains the US FDA’s Orphan Drug Designation to Treat Acute Babesiosis

60 Degrees Pharmaceuticals’ Tafenoquine Gains the US FDA’s Orphan Drug Designation to Treat Acute Babesiosis

  • June 12, 2024

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions
X

Liked our insights or summarized news?

Subscribe to our Daily/Weekly newsletter

Subscribe

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.